Takeda Pharmaceutical (NYSE:TAK) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a strong sell rating to a hold rating in a research note released on Tuesday morning,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Up 1.0%

NYSE:TAK opened at $16.72 on Tuesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.60 and a current ratio of 1.14. Takeda Pharmaceutical has a 52-week low of $12.99 and a 52-week high of $18.90. The stock’s fifty day moving average price is $16.30 and its two-hundred day moving average price is $17.09. The company has a market cap of $53.57 billion, a price-to-earnings ratio of 49.17 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. On average, analysts anticipate that Takeda Pharmaceutical will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Valeo Financial Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 6.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock worth $175,000 after acquiring an additional 632 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Takeda Pharmaceutical by 3.8% in the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after buying an additional 713 shares in the last quarter. Abel Hall LLC increased its stake in Takeda Pharmaceutical by 2.3% in the 1st quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock worth $632,000 after acquiring an additional 781 shares during the last quarter. Private Trust Co. NA lifted its stake in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the last quarter. Finally, Checchi Capital Advisers LLC lifted its holdings in shares of Takeda Pharmaceutical by 5.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock worth $270,000 after acquiring an additional 786 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.